Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells

Cancer Letters

Volumn 354, Issue 1, 2014, Pages 153-163

  Kim, Sung Moo ^a   Lee, Jong Hyun ^a   Sethi, Gautam ^b   Kim, Chulwon ^a   Baek, Seung Ho ^a   Nam, Dongwoo ^a   Chung, Won Seok ^a   Kim, Sung Hoon ^a   Shim, Bum Sang ^a   Ahn, Kwang Seok ^a  

^a Kyung Hee University   (South Korea)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Bergamottin; Multiple myeloma; SHP 1; STAT3

Indexed keywords

BERGAMOTTIN; BORTEZOMIB; CASPASE 3; CYCLIN D1; CYCLOOXYGENASE 2; FUROCOUMARIN; JANUS KINASE 1; JANUS KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE P60; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; THALIDOMIDE; VASCULOTROPIN; PSORALEN DERIVATIVE; PTPN6 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE PRODUCT; GENE SILENCING; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; METASTASIS; MULTIPLE MYELOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GRAPEFRUIT; INFLAMMATION; METABOLISM; SHP-1; TUMOR CELL LINE; TUMOR INVASION;

CITRUS X PARADISI;

APOPTOSIS; BERGAMOTTIN; MULTIPLE MYELOMA; SHP-1; STAT3;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CITRUS PARADISI; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INFLAMMATION; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PSORALENS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84910007055     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.002     Document Type: Article

References (41)

1. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
2. Podar K., Richardson P.G., Hideshima T., Chauhan D., Anderson K.C. The malignant clone and the bone-marrow environment. Best Pract. Res. Clin. Haematol 2007, 20:597-612.
3. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
4. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review). Int. J. Oncol 2012, 41:1181-1191.
5. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol 2003, 171:3863-3871.
6. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
7. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
8. Calo V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., et al. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol 2003, 197:157-168.
9. Ren Z., Schaefer T.S. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J. Biol. Chem 2002, 277:38486-38493.
10. Shodeinde A.L., Barton B.E. Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Oncol. Targets Ther 2012, 5:119-125.
11. Siveen K.S., Sikka S., Surana R., Dai X., Zhang J., Kumar A.P., et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim. Biophys. Acta 1845, 2014:136-154.
12. Trecul A., Morceau F., Dicato M., Diederich M. Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network. Genes Nutr 2012, 7:111-125.
13. Lee J.H., Chiang S.Y., Nam D., Chung W.S., Lee J., Na Y.S., et al. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases. Cancer Lett 2014, 345:140-148.
14. Subramaniam A., Shanmugam M.K., Ong T.H., Li F., Perumal E., Chen L., et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br. J. Pharmacol 2013, 170:807-821.
15. Rajendran P., Li F., Shanmugam M.K., Kannaiyan R., Goh J.N., Wong K.F., et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev. Res 2012, 5:631-643.
16. Rajendran P., Ong T.H., Chen L., Li F., Shanmugam M.K., Vali S., et al. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin. Cancer Res 2011, 17:1425-1439.
17. Willett W.C. Diet and health: what should we eat?. Science 1994, 264:532-537.
18. Bailey D.G., Dresser G.K., Bend J.R. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin. Pharmacol. Ther 2003, 73:529-537.
19. Harapu C.D., Miron A., Cuciureanu M., Cuciureanu R. [Flavonoids-bioactive compounds in fruits juice]. Rev. Med. Chir. Soc. Med. Nat. Iasi 2010, 114:1209-1214.
20. Bailey D.G., Malcolm J., Arnold O., Spence J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol 1998, 46:101-110.
21. Girennavar B., Poulose S.M., Jayaprakasha G.K., Bhat N.G., Patil B.S. Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. Bioorg. Med. Chem 2006, 14:2606-2612.
22. Olguin-Reyes S., Camacho-Carranza R., Hernandez-Ojeda S., Elinos-Baez M., Espinosa-Aguirre J.J. Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic in the Ames test. Food Chem. Toxicol 2012, 50:3094-3099.
23. Han Y., Amin H.M., Franko B., Frantz C., Shi X., Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006, 108:2796-2803.
24. Wu C., Sun M., Liu L., Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003, 306:1-12.
25. Oka T., Ouchida M., Koyama M., Ogama Y., Takada S., Nakatani Y., et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002, 62:6390-6394.
26. Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995, 375:159-161.
27. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci 2006, 1091:151-169.
28. Drobnjak M., Osman I., Scher H.I., Fazzari M., Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res 2000, 6:1891-1895.
29. Han E.K., Lim J.T., Arber N., Rubin M.A., Xing W.Q., Weinstein I.B. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998, 35:95-101.
30. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol 1993, 143:401-409.
31. Pandey M.K., Sung B., Aggarwal B.B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int. J. Cancer 2010, 127:282-292.
32. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
33. Mitra R., Guo Z., Milani M., Mesaros C., Rodriguez M., Nguyen J., et al. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (+/-)-14,15-epoxyeicosatrienoic acid (EET). J. Biol. Chem 2011, 286:17543-17559.
34. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol 2006, 71:713-721.
35. Zhao M., Jiang B., Gao F.H. Small molecule inhibitors of STAT3 for cancer therapy. Curr. Med. Chem 2011, 18:4012-4018.
36. Tu Y., Renner S., Xu F., Fleishman A., Taylor J., Weisz J., et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998, 58:256-262.
37. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006, 20:1341-1352.
38. Glasmacher A., Hahn C., Hoffmann F., Naumann R., Goldschmidt H., von Lilienfeld-Toal M., et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol 2006, 132:584-593.
39. Rajendran P., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J. Cell. Physiol 2012, 227:2184-2195.
40. Kannaiyan R., Hay H.S., Rajendran P., Li F., Shanmugam M.K., Vali S., et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol 2011, 164:1506-1521.
41. Rajendran P., Li F., Manu K.A., Shanmugam M.K., Loo S.Y., Kumar A.P., et al. Gamma-tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br. J. Pharmacol 2011, 163:283-298.